Knight Therapeutics Inc.

GUD

CA4990531069

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 10:22:48 2024-04-25 am EDT			5-day change	1st Jan Change
5.66 ^CAD	-1.05%		-2.25%	+9.06%

Mar. 22	Knight Therapeutics Price Target Raised to $7 at RBC	MT
Mar. 21	Knight Therapeutics Reports Fourth Quarter Results	MT

Knight Therapeutics Inc. Promotes Amal Khouri to Chief Business Officer

May 14, 2021 at 07:43 am EDT

Knight Therapeutics Inc. announced that it has Promoted Amal Khouri to Chief Business Officer.

Latest news about Knight Therapeutics Inc.

Knight Therapeutics Price Target Raised to $7 at RBC	Mar. 22	MT
Knight Therapeutics Reports Fourth Quarter Results	Mar. 21	MT
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024	Mar. 21	CI
Transcript : Knight Therapeutics Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Knight Therapeutics Inc. Announces Impairment Charges for the Fourth Quarter of 2023	Mar. 21	CI
Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
North American Morning Briefing : Investors -2-	Mar. 21	DJ
North American Morning Briefing : Investors Continue to Cheer Reassuring Fed	Mar. 21	DJ
Knight Therapeutics Announces Launch of Minjuvi in Brazil	Feb. 29	MT
Knight Therapeutics Brief: Announcing Launch of Minjuvi in Brazil	Feb. 29	MT
Knight Therapeutics Brief: Announcing Regulatory Submission Of Fostamatinib In Brazil	Feb. 21	MT
Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil	Feb. 21	CI
Knight Therapeutics Announces Launch of Bijuva in Canada	Feb. 06	MT
Knight Therapeutics Brief: Announcing Launch of Bijuva in Canada	Feb. 06	MT
Knight Therapeutics Inc. Announces Launch of Bijuva® in Canada	Feb. 06	CI
Amneal Grants Knight Therapeutics Rights to Parkinson's Disease Drug in Canada, Latin America	Jan. 25	MT
Knight Therapeutics Enters Into License Agreement With Amneal Pharmaceuticals For Parkinson's Disease Treatment	Jan. 25	MT
Knight Therapeutics Brief: Entering Into Exclusive License Agreement With Amneal Pharmaceuticals For IPX203	Jan. 25	MT
Basilea Pharmaceutica to Receive First Milestone Payment for Cresemba from Latin America	Jan. 19	MT
Knight Therapeutics Announces Product Launch For IMVEXXY In Canada	Jan. 04	MT
Knight Therapeutics Inc. Announces Product Launch for IMVEXXY in Canada	Jan. 04	CI
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada	Dec. 19	MT
Knight Therapeutics Brief: Entering into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada	Dec. 19	MT
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada	Dec. 19	CI

Chart Knight Therapeutics Inc.

Duration

Period

More charts

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Knight Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.72 CAD

Average target price

6.729 CAD

Spread / Average Target

+17.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
KNIGHT THERAPEUTICS INC.	+9.06%	422M
MERCK KGAA	+3.85%	70.78B
KYOWA KIRIN CO. LTD.	+10.72%	9.15B
SK BIOPHARMACEUTICALS CO., LTD.	-15.34%	4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+34.54%	4.22B
YUHAN CORPORATION	+5.09%	3.92B
INDIVIOR PLC	+17.97%	2.55B
BETTA PHARMACEUTICALS CO., LTD.	-24.15%	2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.33%	2.24B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+6.23%	1.92B

Specialty & Advanced Pharmaceuticals